In 2019, the FDA approved a new nasal spray medication identified as esketamine (Spravato), a sort of ketamine, to be used with the oral antidepressant for those with important depressive problem (MDD) who may have treatment-resistant depression. This announcement outlined the main psychedelic-like drug being accredited for lawful use; Some others,… Read More